DrugPatentWatch Database Preview
Deferiprone - Generic Drug Details
» See Plans and Pricing
What are the generic sources for deferiprone and what is the scope of patent protection?
Deferiprone
is the generic ingredient in two branded drugs marketed by Chiesi and Taro Pharm Inds Ltd, and is included in four NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Deferiprone has fifty-three patent family members in twenty-six countries.
There are four drug master file entries for deferiprone. Three suppliers are listed for this compound.
Summary for deferiprone
| International Patents: | 53 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Applicants: | 2 |
| NDAs: | 4 |
| Drug Master File Entries: | 4 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 100 |
| Clinical Trials: | 58 |
| Patent Applications: | 1,252 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for deferiprone |
| DailyMed Link: | deferiprone at DailyMed |
Recent Clinical Trials for deferiprone
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| First Affiliated Hospital of Fujian Medical University | Early Phase 1 |
| David Hasan | Phase 2 |
| Ministry of Health, France | Phase 2/Phase 3 |
Pharmacology for deferiprone
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity |
Paragraph IV (Patent) Challenges for DEFERIPRONE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| FERRIPROX | TABLET;ORAL | deferiprone | 021825 | 2016-01-29 |
US Patents and Regulatory Information for deferiprone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-002 | Jul 25, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-002 | Apr 20, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Taro Pharm Inds Ltd | DEFERIPRONE | deferiprone | TABLET;ORAL | 208800-001 | Feb 8, 2019 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-001 | Sep 9, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for deferiprone
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201071235 | Start Trial |
| Australia | 2001270402 | Start Trial |
| South Korea | 101490721 | Start Trial |
| South Korea | 20100135316 | Start Trial |
| European Patent Office | 3684344 | Start Trial |
| Brazil | 0112280 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
